| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:2285-2289.)
© 2004 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Cardiology, St Jamess University Hospital, Leeds, UK.
Correspondence to Dr Lee N. Graham, Department of Cardiology, St Jamess University Hospital, Beckett Street, Leeds, UK. E-mail lee{at}graham93.fsnet.co.uk
Received November 5, 2003; de novo received January 19, 2004; accepted February 13, 2004.
| Abstract |
|---|
|
|
|---|
Methods and Results Thirty-nine patients with uncomplicated AMI, comprising 2 matched groups of 17 patients with ant-AMI, and 22 patients with inf-AMI were examined. Measurements were obtained 2 to 4 days after AMI and compared with 20 normal subjects (NC) who were matched in terms of age and body weight to the AMI groups. Resting muscle sympathetic nerve activity was quantified from multiunit bursts (MSNA) and from single units (s-MSNA). Both groups of AMI patients were matched with regard to hemodynamic variables, left ventricular function, and infarct size. Both groups had greater (at least P<0.01) sympathetic nerve activity than NC (60±4.3 bursts/100 cardiac beats and 68±4.9 impulses/100 cardiac beats), but the magnitude of sympathetic nerve hyperactivity in ant-AMI (81±4.0 bursts/100 cardiac beats and 91±4.9 impulses/100 cardiac beats) was similar (P>0.05) to that in inf-AMI (80±3.2 bursts/100 cardiac beats and 90±4.0 impulses/100 cardiac beats)
Conclusions Both ant-AMI and inf-AMI resulted primarily in a similar magnitude of sympathetic nerve hyperactivity. These findings suggest that the worse prognosis after ant-AMI compared with after inf-AMI would not be related primarily to the degree of sympathetic hyperactivity.
Key Words: nervous system, sympathetic myocardial infarction action potentials
| Introduction |
|---|
|
|
|---|
Adverse prognosis after AMI has been associated with factors such as advanced age, larger infarcts, and left ventricular systolic dysfunction,512 conditions in which a disproportionate sympathetic activation is known to occur.1,2,13 However, although the prognosis after ant-AMI is poorer than after inf-AMI,5,8,14,15 it is as yet unknown whether sympathetic nerve hyperactivity occurs to a greater extent in the former than the latter. The only available information has been derived from experimental studies in animals. For instance, after the demonstration of a sympatho-sympathetic cardiac reflex,16 other reports have reported that excitation of left ventricular sympathetic afferents is a significant mechanism leading to sympathetic activation after acute myocardial ischemia and infarction.1719 These afferents are evenly distributed in the walls of the left ventricle, such that their excitation at any site causes similar reflex efferent sympathetic activation.20 Indeed, in humans, plasma norepinephrine levels have been reported to increase to a similar extent in patients who sustain either an ant-AMI or inf-AMI.21 However, plasma norepinephrine levels are a crude estimate of sympathetic output,22 and there are no available data from direct measurements of sympathetic nerve activity.
The present investigation was therefore designed to determine whether the magnitude of sympathetic nerve hyperactivity early after ant-AMI is different from that after inf-AMI. For this purpose, we quantified sympathetic nerve hyperactivity relative to normal controls in 2 groups of patients within 4 days of sustaining ant-AMI or inf-AMI who were closely matched in terms of age, body weight, left ventricular systolic function, and peak cardiac enzyme levels.
| Methods |
|---|
|
|
|---|
|
AMI was confirmed by the following criteria: (1) a clinical history of ischemic-type chest pain, (2) changes on serially obtained ECGs, and (3) a rise in serum creatine kinase (CK) levels to >400 IU/L and their subsequent fall. The location of the infarct was obtained from analysis of the ECG according to the Minnesota code23 and was subsequently confirmed by the finding of a regional wall motion abnormality with 2D echocardiography and by coronary angiography and left ventriculography. In all patients, coronary artery disease was confirmed by both exercise treadmill testing and coronary angiography. A positive exercise test was defined by horizontal ST-segment depression of at least 2 mm during exercise with associated chest pain. Coronary angiography demonstrated significant coronary artery disease in these patients (>70% stenosis of at least 1 major epicardial coronary artery).
All patients were in Killip class I, and none had frequent ventricular ectopic beats or conduction defects, chest rales, or radiographic evidence of pulmonary vascular congestion. Also, none had a left ventricular ejection fraction (LVEF) of <40% as determined by echocardiography. Patients with ant-AMI and inf-AMI received conventional therapy in the form of thrombolysis (n=15 and 21), ß-blockers (n=15 and 18), and ACE inhibitors (n=13 and 15). None had undergone any revascularization procedure. The 2 groups, respectively, had single-vessel disease (n=10 and 14), 2-vessel disease (n=4 and 7), and 3-vessel disease (n=3 and 1). The investigation was performed with the approval of St Jamess University Hospital Ethics Committee, and all subjects provided informed written consent.
General Protocol
Sympathetic activity in AMI patients was assessed at 2 to 4 days after admission. The same protocol was performed between the hours of 9:00 AM and 12:00 noon for all groups as previously reported.4 Subjects were asked to have a light breakfast and to empty their bladder before commencing the study and were requested to avoid alcohol, nicotine, and caffeine products for 12 hours before investigation.
During each session, the subjects were studied in the semisupine position. Measurements were made in a darkened laboratory in which the temperature was constant at 22°C to 24°C. Resting blood pressure was measured from the arm with a standard mercury sphygmomanometer. Heart rate and arterial blood pressure were monitored and recorded with a standard ECG and a Finapres device, and blood flow to the muscle of the left calf was obtained by use of standard strain-gauge plethysmography.
Microneurography
Postganglionic muscle sympathetic nerve activity (MSNA) was recorded from the right peroneal nerve for 5 minutes after subjects had attained steady state for at least 30 minutes with regard to measured variables as previously described.4 The neural signal was amplified (x50 000), and for the purpose of generating bursts representing multiunit discharge, the signal was filtered (bandwidth of 700 to 2000 Hz) and integrated (time constant, 0.1 second). The output of action potentials and bursts from this assembly were passed to a data-acquisition system, which digitized the action potentials at 12 000 samples per second and other data channels at 2000 samples per second (8 bits).
Single units (s-MSNA) in the raw action potential neurogram were obtained by adjusting the electrode position while using fast monitor sweep and online storage oscilloscope to confirm the presence of a consistent action potential morphology, as previously described.24,25 Only vasoconstrictor units were accepted and examined, the criteria of acceptance being appropriate responses to spontaneous changes in arterial blood pressure, the Valsalva maneuver, and isometric hand-grip exercise. Simultaneous measurement of calf vascular resistance confirmed the vasoconstrictor function of the observed neural activity. During the Valsalva maneuver, sympathetic activity increased during the latter part of phase II and/or phase III and decreased during phase IV (increase and overshoot of blood pressure). Isometric hand-grip exercise, performed with a dynamometer, produced a late increase in arterial blood pressure and sympathetic neural activity.
An electronic discriminator was used objectively to count the spikes of s-MSNA and was quantified as mean frequency of impulses/min and also as impulses/100 cardiac beats to avoid any interference by the length of the cardiac cycle.26 The bursts of MSNA were identified by inspection when the signal-to-noise ratio was >3 and were quantified in a similar manner. The variability of measuring both s-MSNA and MSNA in this laboratory did not exceed 10%.25 LVEF was determined by 2D echocardiography (Toshiba SSA-380A, Toshiba Corp). Briefly, left ventricular wall motion was assessed visually by use of a 9-segment model and graded as previously described in patients with myocardial infarction.27,28 The following scores were used: 3 for hyperkinesia, 2 for normokinesia, 1 for hypokinesia, 0 for akinesia, and 1 for dyskinesia. Wall motion index was calculated by dividing the sum of the scores in each individual segment by 9. Wall motion index multiplied by 0.3 gave the estimate of LVEF.
Statistics
One-way ANOVA with Newman-Keuls post hoc tests was used to compare data between the 3 groups of subjects. Students t test was used to compare unpaired data available only in patients with ant-AMI and inf-AMI. The least-squares technique was used for assessing the linear relationship between variables. Values of P<0.05 were considered statistically significant. Data are presented as mean±SEM.
| Results |
|---|
|
|
|---|
2=0.58; P>0.1). The indices of arterial blood pressure in ant-AMI were similar to those with inf-AMI, although as expected, they were lower in the 2 AMI groups than in NC. There were also no significant differences between ant-AMI and inf-AMI with regard to LVEF or peak CK levels (Table). All indices of sympathetic nerve activity were significantly greater in ant-AMI and inf-AMI than in NC. However, all indices of sympathetic activity in ant-AMI were similar to those in inf-AMI (Table; Figure). In both of the AMI groups, there was a significant negative correlation between indices of sympathetic activity and LVEF (at least r=0.45, P<0.02), although there was no correlation between sympathetic activity and peak CK levels (at least r=0.06; P>0.40).
|
In each of the 3 groups, the indices of sympathetic nerve activity were positively correlated to age (at least r=0.59; P<0.008) but not to indices of arterial blood pressure (at least r=0.34; P>0.07).
| Discussion |
|---|
|
|
|---|
Although MSNA is limited to exploring efferent peripheral discharge, our findings that both groups of AMI had greater MSNA than normal controls is consistent with previous reports using different techniques, showing sympathetic activation early after AMI.13 All 3 groups in the present study were examined under the same laboratory conditions to avoid confounding influences related to circadian variation,29 alcohol,30 visceral distension, and a large meal.31,32 In addition, all groups were closely matched to avoid confounding factors such as age, gender,13 race,33 body weight,34 and heart rate.26 Unavoidably, the 2 groups with AMI were receiving ß-blocker or ACE inhibitor therapy and as a result had a slightly lower arterial pressure than the NC subjects. However, we found no correlation between sympathetic nerve activity and indices of arterial pressure as previously reported in other clinical conditions,4,25 supporting the proposal that sympathetic excitation was independent of baroreceptor reflex function.19 Also, we have previously shown that the sympathetic hyperactivity early after AMI persisted for at least 3 months despite normalization of arterial pressure.4 With regard to therapy, it has been reported in patients with heart failure that ACE inhibitors decrease sympathetic nerve activity35 and that ß-blockers have no effect on MSNA.36 Also, we have previously shown that after AMI, MSNA was greater than in control groups receiving the same therapeutic agents, including patients with stable coronary artery disease and patients hospitalized with chest pain in whom AMI was excluded.4 These treated control groups had the same level of MSNA as that in untreated matched normal controls.4 These considerations make it likely that no single factor other than AMI could have resulted in the observed sympathetic hyperactivity.
With regard to the site of the infarct, our findings were obtained 2 to 4 days after AMI, at a time when patients had no discernible clinical complications and their LVEF was >40%. Both groups were closely matched to avoid interfering effects on sympathetic nerve activity by factors including arterial pressure,25,37 peak serum CK levels, and degree of left ventricular dysfunction.1,2 In addition, both groups received similar therapy. Such considerations make it unlikely that confounding factors would have unequivocally explained the similarity of the magnitude of sympathetic hyperactivity between ant-AMI and inf-AMI.
Our findings have implications with regard to the mechanism of the sympathetic nerve hyperactivity observed after AMI. One of the postulated mechanisms of sympathetic activation after acute myocardial ischemia or infarction has involved chemical activation or impairment of sympathetic or vagal afferents, respectively, and their interaction.1719 There has been experimental evidence showing that sympathetic afferents are evenly distributed throughout the anterior and inferoposterior walls of the left ventricle and that their activation by chemicals or ischemia in any of these locations leads to a similar reflex sympathetic activation.20 In contrast, the chemosensitive vagal afferents, the excitation of which leads to sympathetic inhibition, are located primarily in the inferoposterior walls of the left ventricle.38
Reports in humans seem to support the view that excitation of ventricular sympathetic afferents is the predominant mechanism of efferent sympathetic activation after AMI. For instance, plasma norepinephrine levels increase to a similar extent in patients developing either ant-AMI or inf-AMI.21 Within the first hours of developing infarction, excessive vagal discharge has been related to bradyarrhythmia and sudden death that occur in the case of posterior AMI.39 Using changes in heart rate and arterial pressure that occurred within 1 hour after the onset of posterior AMI, a predominance of parasympathetic effects was found to occur early, whereas sympathetic predominance occurred late within the hour after ant-AMI.40 In addition, sympathetic activation and diminished vagal modulation of the heart period have been reported
3 hours after ant-AMI and inf-AMI, although they occurred to a greater extent in ant-AMI.3 Taken together, these reports3,39,40 indicate that any vagal overactivity and its confounding effect on sympathetic activation was short-lasting.3 The present study was therefore conducted 2 to 4 days after AMI, with the patients in a stable condition, to avoid the volatile phase of autonomic disturbance very early after infarction and also any other confounding factors that might interfere with the sympathetic drive, such as the complications of arrhythmia and heart failure. Our finding in each of the 2 AMI groups of an inverse correlation between sympathetic hyperactivity and LVEF is consistent with a predominant effect of excitation of sympathetic over vagal afferents, because the former leads to efferent sympathetic activation, whereas the latter leads to sympathetic inhibition. These considerations make it possible to propose that the efferent sympathetic activation after AMI has involved excitation of ventricular sympathetic afferents.
The other implications of the present study relate to reported factors that may potentially result in a greater mortality and morbidity in association with ant-AMI than with inf-AMI.5,8,14,15 These factors have included age, extent of left ventricular dysfunction, infarct size, and development of heart failure.4144 It is notable that most of these factors result in sympathetic activation,1,2,13 which in turn is believed to lead to an adverse outcome.1,2,21 In addition, it is known that the increased mortality associated with ant-AMI occurs during the first few hours after the onset of infarction.40 However, both AMI groups in the present study were clinically stable, had no complications, and were matched for confounding factors, particularly LVEF and peak CK levels. Therefore, our data that were obtained 2 to 4 days after AMI indicate that the site of infarction alone does not influence the magnitude of sympathetic nerve hyperactivity and suggest that the eventual poorer prognosis after ant-AMI than inf-AMI is not related primarily to differences in the magnitude of sympathetic hyperactivity.
In conclusion, the findings of the present study indicate that the magnitude of sympathetic nerve hyperactivity seen 2 to 4 days after uncomplicated AMI is similar between ant-AMI and inf-AMI. The findings suggest that excitation of the evenly distributed sympathetic afferents within the left ventricle constitute an important mechanism for efferent sympathetic activation.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
2. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohumoral activation following acute myocardial infarction. Am Heart J. 1993; 126: 10681076.[CrossRef][Medline] [Order article via Infotrieve]
3. Lombardi F, Sandrone G, Spinnler MT, et al. Heart rate variability in the early hours of an acute myocardial infarction. Am J Cardiol. 1996; 77: 10371044.[CrossRef][Medline] [Order article via Infotrieve]
4. Graham LN, Smith PA, Stoker JB, et al. Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation. 2002; 106: 793797.
5. Beaune J, Touboul P, Boissel JP, et al. Quantitative assessment of myocardial infarction prognosis to 1 and 6 mth from clinical data. Eur J Cardiol. 1978; 8: 629647.[Medline] [Order article via Infotrieve]
6. Hands ME, Rutherford JD, Muller JE, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol. 1989; 14: 4046.[Abstract]
7. Kober L, Torp-Pedersen C, Ottesen M, et al. Influence of age on the prognostic importance of left ventricular dysfunction and congestive heart failure on long-term survival after acute myocardial infarction. TRACE Study Group. Am J Cardiol. 1996; 78: 158162.[Medline] [Order article via Infotrieve]
8. Danchin N, Vaur L, Genes N, et al. Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results. J Am Coll Cardiol. 1997; 30: 15981605.[Abstract]
9. French JK, Hyde TA, Patel H, et al. Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol. 1999; 34: 6269.
10. Capewell S, Livingston BM, MacIntyre K, et al. Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J. 2000; 21: 18331840.
11. Webber BJ, McLaughlin SC, Whitlock RM, et al. Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction. J Am Coll Cardiol. 2000; 35: 15161524.
12. Marchioli R, Avanzini F, Barzi F, et al, for the GISSI-Prevenzione Investigators. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J. 2001; 22: 20852103.
13. Ng AV, Callister R, Johnson DG, et al. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension. 1993; 21: 498503.
14. Gruppo Italiano per lo Studio della Sopravvivenza nellInfarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990; 336: 6571.[Medline] [Order article via Infotrieve]
15. Behar S, Rabinowitz B, Zion M, et al. Immediate and long-term prognostic significance of a first anterior versus first inferior wall Q-wave acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group. Am J Cardiol. 1993; 72: 13661370.[CrossRef][Medline] [Order article via Infotrieve]
16. Malliani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol. 1969; 217: 703709.
17. Thames MD, Dibner-Dunlap ME, Minisi AJ, et al. Reflexes mediated by cardiac sympathetic afferents during myocardial ischaemia: role of adenosine. Clin Exp Pharmacol Physiol. 1996; 23: 709714.[Medline] [Order article via Infotrieve]
18. Longhurst JC, Tjen-A-Looi SC, Fu LW. Cardiac sympathetic afferent activation provoked by myocardial ischemia and reperfusion: mechanisms and reflexes. Ann N Y Acad Sci. 2001; 940: 7495.[Medline] [Order article via Infotrieve]
19. Malliani A, Montano N. Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions. Hypertension. 2002; 39: 6368.
20. Minisi AJ, Thames MD. Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circulation. 1993; 87: 240246.
21. Karlsberg RP, Cryer PE, Roberts R. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J. 1981; 102: 2429.[CrossRef][Medline] [Order article via Infotrieve]
22. Esler MD, Jennings G, Lambert G, et al. Overflow of catecholamines neurotransmitters to the circulation: source, fate and functions. Physiol Rev. 1990; 70: 963985.
23. Rose GA, Blackburn H. Cardiovascular Survey Methods. WHO Monograph Series, No 56. Geneva, Switzerland: World Health Organization; 1968.
24. Macefield VG, Wallin BG, Vallbo AB. The discharge behaviour of single vasoconstrictor motoneurones in human muscle nerves. J Physiol (Lond). 1994; 481: 799809.
25. Greenwood JP, Stoker JB, Mary DASG. Single-unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation. 1999; 100: 13051310.
26. Sundlöf G, Wallin BG. The variability of muscle nerve sympathetic activity in resting recumbent man. J Physiol (Lond). 1977; 272: 383397.
27. Heger JJ, Weyman AE, Wann LS, et al. Cross-sectional echocardiographic analysis of left ventricular asynergy in acute myocardial infarction. Circulation. 1980; 61: 11131118.
28. Berning J, Rokkedal Nielson J, Launbjerg J, et al. Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology. 1992; 80: 257266.[Medline] [Order article via Infotrieve]
29. Hartikainen J, Tarkiainen I, Tahvanainen K, et al. Circadian variation of cardiac autonomic regulation during 24-h bed rest. Clin Physiol. 1993; 13: 185196.[Medline] [Order article via Infotrieve]
30. Grassi GM, Somers VK, Renk WS, et al. Effects of alcohol intake on blood pressure and sympathetic nerve activity in normotensive humans: a preliminary report. J Hypertens. 1989; 7 (suppl): S20S21.
31. Fagius H, Karhuvaara S. Sympathetic activity and blood pressure increases with bladder distension in humans. Hypertension. 1989; 14: 511517.
32. Cox HS, Kaye DM, Thompson JM, et al. Regional sympathetic nervous activation after a large meal in humans. Clin Sci (Colch). 1995; 89: 145154.[Medline] [Order article via Infotrieve]
33. Calhoun DA, Mutinga ML, Collins AS, et al. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension. 1993; 22: 801805.
34. Scherrer U, Randin D, Tappy L, et al. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994; 89: 26342640.
35. Grassi G, Cattaneo BM, Servalle G, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 1997; 96: 11731179.
36. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective ß-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation. 2001; 104: 21942199.
37. Anderson EA, Sinkey CA, Lawton WJ, et al. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1989; 14: 177183.
38. Inoue H, Zipes DP. Increased afferent vagal responses produced by epicardial application of nicotine on the canine posterior left ventricle. Am Heart J. 1987; 114: 757764.[CrossRef][Medline] [Order article via Infotrieve]
39. Adgey AA, Geddes JS, Mulholland HC, et al. Incidence, significance, and management of early bradyarrhythmia complicating acute myocardial infarction. Lancet. 1968; 2: 10971101.[Medline] [Order article via Infotrieve]
40. Pantridge JF, Webb SW, Adgey AA. Arrhythmias in the first hours of acute myocardial infarction. Prog Cardiovasc Dis. 1981; 23: 265278.[CrossRef][Medline] [Order article via Infotrieve]
41. Stadius ML, Davis K, Maynard C, et al. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial. Circulation. 1986; 74: 703711.
42. Hands ME, Lloyd BL, Robinson JS, et al. Prognostic significance of electrocardiographic site of infarction after correction for enzymatic size of infarction. Circulation. 1986; 73: 885891.
43. Maisel AS, Gilpin E, Hoit B, et al. Survival after hospital discharge in matched populations with inferior or anterior myocardial infarction. J Am Coll Cardiol. 1985; 6: 731736.[Abstract]
44. Thanavaro S, Kleiger RE, Province MA, et al. Effect of infarct location on the in-hospital prognosis of patients with first transmural myocardial infarction. Circulation. 1982; 66: 742747.
This article has been cited by other articles:
![]() |
D. C. Parrish, K. Gritman, D. M. Van Winkle, W. R. Woodward, M. Bader, and B. A. Habecker Postinfarct sympathetic hyperactivity differentially stimulates expression of tyrosine hydroxylase and norepinephrine transporter Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H99 - H106. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hainsworth and M. J. Drinkhill COUNTERPOINT: ACTIVE VENOCONSTRICTION IS NOT IMPORTANT IN MAINTAINING OR RAISING END-DIASTOLIC VOLUME AND STROKE VOLUME DURING EXERCISE AND ORTHOSTASIS J Appl Physiol, October 1, 2006; 101(4): 1264 - 1265. [Full Text] [PDF] |
||||
![]() |
REBUTTAL FROM DRS. HAINSWORTH AND DRINKHILL J Appl Physiol, October 1, 2006; 101(4): 1266 - 1266. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |